Cardiovascular Disease Early Detection and Prevention Act of 2026
- Bill Number
- H.R. 8260
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Status
- Introduced
- Latest Action
- 2026-04-14: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-04-17T08:23:37Z
AI-Generated Summary
Purpose
The Cardiovascular Disease Early Detection and Prevention Act of 2026 (H.R. 8260) aims to improve early detection of cardiovascular risks by requiring health insurance plans and government programs to cover specific blood tests for lipoprotein(a) [Lp(a)] (a type of cholesterol linked to heart disease) and apolipoprotein B [ApoB] (a protein that predicts heart risk better than standard cholesterol tests) without any out-of-pocket costs (like copays or deductibles) for at-risk individuals.
Key Provisions
- Coverage Requirements:
- Applies to group health plans, individual health insurance, Medicare, and Medicaid.
- Tests must be covered for people with:
- Family history of early cardiovascular disease.
- Personal history of heart attack (myocardial infarction), stroke, or high LDL cholesterol.
- Diagnosis of diabetes or obesity.
- Other recognized heart risk factors.
- No Cost Sharing: Patients pay nothing for these tests under all covered programs.
- Effective Dates:
- Private insurance: Plan years starting 180 days after enactment.
- Medicare and Medicaid: Services provided on or after enactment date.
- Congressional Findings: Highlights cardiovascular disease as the top U.S. killer; notes standard cholesterol tests miss Lp(a) and ApoB elevations (affecting 1 in 5 Americans); elevated ApoB better predicts risk; many heart attack survivors die soon without better management.
Significant Changes to Existing Law
- Public Health Service Act (Section 2713): Adds Lp(a) and ApoB tests to the list of preventive services covered without cost sharing (previously included things like cancer screenings).
- Medicare (Social Security Act Sections 1861, 1833): Classifies these tests as covered preventive services with no deductibles or copays; updates definitions to include them.
- Medicaid (Social Security Act Sections 1905, 1916, etc.): Mandates coverage as a required benefit; prohibits cost sharing; ensures benchmark plans include it.
These amendments expand no-cost preventive care mandates (similar to Affordable Care Act provisions) to these new tests.
Potential Impacts
- On Citizens: Easier access to early risk detection for millions at risk, potentially preventing heart attacks/strokes and saving lives.
- On Government Agencies: Centers for Medicare & Medicaid Services (CMS) must implement and enforce; could raise program costs from increased testing.
- On Insurers/Employers: Higher short-term costs for mandatory coverage, but possible long-term savings from preventing expensive treatments.
- Healthcare System: Boosts use of advanced lipid testing, improving overall heart disease prevention.
Main Stakeholders
- Individuals: Those with family/personal heart risks, diabetes, obesity (about 1 in 5 Americans for Lp(a)).
- Health Insurers and Employers: Must provide no-cost coverage in group/individual plans.
- Medicare/Medicaid Beneficiaries and States: Expanded benefits; states cannot opt out in benchmark plans.
- Healthcare Providers: Simplified billing for tests; potential increase in orders.
- Government: Congress, HHS, CMS for oversight and funding.
Notable Legal, Constitutional, or Political Implications
- Legal: Builds on existing preventive care laws without new funding mechanisms; enforceable via current regulatory frameworks.
- Constitutional: No apparent challenges (aligns with Congress's commerce and spending powers for health programs).
- Political: Increases federal mandates on private insurers and states, similar to ACA expansions; may spark debates on costs vs. preventive benefits.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Cherfilus-McCormick, Sheila [D-FL-20]
Recent Actions
- 2026-04-14: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2026-04-14: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2026-04-14: Introduced in House
- 2026-04-14: Introduced in House
Bill Versions
- Cardiovascular Disease Early Detection and Prevention Act of 2026 — issued 2026-04-14 — PDF (7 pages)